Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | PPARD | Q03181 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL8905153 | 1.00 | TYMS (0.41) | TYMSHSD17B10KDM4EMMP2THRB | |
| Phosphoric Acid SCHEMBL6219162 | 1.00 | TYMS (0.41) | TYMSHSD17B10KDM4EMMP2THRB | |
| Phosphoric Acid SCHEMBL16567884 | 1.00 | TYMS (0.41) | TYMSHSD17B10KDM4EMMP2THRB | |
| Phosphoric Acid SCHEMBL16568053 | 1.00 | TYMS (0.41) | TYMSHSD17B10KDM4EMMP2THRB | |
| 1,4-Butanediol SCHEMBL27437351 | 0.92 | TYMS (0.41) | TYMSHSD17B10KDM4EMMP2THRB | |
| 1,4-Butanediol SCHEMBL28692 | 0.92 | TYMS (0.41) | TYMSHSD17B10KDM4EMMP2THRB | |
| Phosphoric Acid SCHEMBL9551052 | 0.88 | GPR84 (0.45) | TYMSHSD17B10KDM4EMMP2THRB | |
| Phosphoric Acid SCHEMBL28170316 | 0.88 | GPR84 (0.45) | TYMSHSD17B10KDM4EMMP2THRB | |
| 1,6-Hexanediol SCHEMBL20582374 | 0.88 | GPR84 (0.45) | TYMSHSD17B10KDM4EMMP2THRB | |
| 1,6-Hexanediol SCHEMBL27687126 | 0.88 | GPR84 (0.45) | TYMSHSD17B10KDM4EMMP2THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10781449-B2 | Double-stranded oligonucleotide molecules targeting p53 and methods of use thereof | QUARK PHARMACEUTICALS, INC. (US) | 2020-09-22 | — | — | US | claimed |
| CN-105473185-B | A moisturizing composition that can be applied to wet skin in the form of an oil-in-water emulsion; moisturizing nursing method | 莱雅公司 | 2020-04-28 | — | — | CN | claimed |
| US-9932578-B2 | Double-stranded oligonucleotide molecules to P53 and methods of use thereof | QUARK PHARMACEUTICALS, INC. (US) | 2018-04-03 | — | — | US | claimed |
| WO-2016116073-A1 | CHIRAL RESOLUTION OF BEDAQUILINE BY USING CYCLCIC PHOSPHORIC ACIDS | ZENTIVA, K.S. (CZ) | 2016-07-28 | — | — | WO | claimed |
| CN-105473185-A | A moisturizing composition that can be applied to wet skin in the form of an oil-in-water emulsion; moisturizing nursing method | L'OREAL S A | 2016-04-06 | — | — | CN | claimed |
| CN-117844197-A | Multifunctional clothing material and preparation method thereof | 湖南圣得西时尚科技有限公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-113766906-A | Cosmetic composition in the form of a soft solid comprising a hydrophobic powder selected from silica aerogel and polylactic acid, starch and a UV filter system | 欧莱雅 | 2021-12-07 | — | — | CN | disclosed |
| CN-105722497-B | Foaming composition comprising at least one glycinate surfactant | 欧莱雅 | 2020-05-15 | — | — | CN | disclosed |
| CN-105473185-B | A moisturizing composition that can be applied to wet skin in the form of an oil-in-water emulsion; moisturizing nursing method | 莱雅公司 | 2020-04-28 | — | — | CN | disclosed |
| US-9611505-B2 | Application of oligo-DT molecules to avoid generation of high molecular PCR products induced by poly-A carrier | ROCHE MOLECULAR SYSTEMS, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| WO-2016116073-A1 | CHIRAL RESOLUTION OF BEDAQUILINE BY USING CYCLCIC PHOSPHORIC ACIDS | ZENTIVA, K.S. (CZ) | 2016-07-28 | — | — | WO | disclosed |
| WO-2016116073-A1 | CHIRAL RESOLUTION OF BEDAQUILINE BY USING CYCLCIC PHOSPHORIC ACIDS | ZENTIVA, K.S. (CZ) | 2016-07-28 | — | — | WO | disclosed |
| WO-2011085056-A1 | OLIGONUCLEOTIDE COMPOUNDS COMPRISING NON-NUCLEOTIDE OVERHANGS | QUARK PHARMACEUTICALS, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| WO-2011072082-A2 | MODULATION OF HSP47 EXPRESSION | NITTO DENKO CORPORATION (JP) | 2011-06-16 | — | — | WO | disclosed |
| WO-2009042291-A2 | ACCELERATED CASCADE AMPLIFICATION (ACA) OF NUCLEIC ACIDS COMPRISING STRAND AND SEQUENCE SPECIFIC DNA NICKING | KUTYAVIN IGOR (US) | 2009-04-02 | — | — | WO | disclosed |
| US-20090047678-A1 | ACCELERATED CASCADE AMPLIFICATION (ACA) OF NUCLEIC ACIDS COMPRISING STRAND AND SEQUENCE SPECIFIC DNA NICKING | KUTYAVIN IGOR | 2009-02-19 | — | — | US | disclosed |
| WO-2006107060-A1 | WATER SOLUBLE POLYMER COMPOSITION | NIPPON SHOKUBAI CO., LTD. (JP) | 2006-10-12 | — | — | WO | disclosed |
| US-20030139585-A1 | Synthetic double-stranded oligonucleotides for specific inhibition of gene expression | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-07-24 | — | — | US | disclosed |
| EP-0663918-A1 | PURE ENANTIOMERS OF PHOSPHORIC-ACID ESTERS AS PHOSPHOLIPASE-A2 INHIBITORS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1995-07-26 | — | — | EP | disclosed |
| WO-1994009014-A1 | PURE ENANTIOMERS OF PHOSPHORIC-ACID ESTERS AS PHOSPHOLIPASE-A2 INHIBITORS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1994-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139585-A1 | Synthetic double-stranded oligonucleotides for specific inhibition of gene expression | DCLRE1B, RIOX2, SRRT | TYMS 76/4885HSD17B10 1414/4885KDM4E 4338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.